$100m-$499m

Poynt takes $100m series C payment
Backed by Stanford-Start X Fund and a trio of corporates, Poynt has now received more than $128m in total for its payment processing terminal and software business.
Amgen inserts $66m into Oxford Nanopore
Oxford Nanopore has secured $66m from Amgen, after the latter’s subsidiary Decode Genetics used the spinout’s technology to sequence hundreds of human genomes.
Atreca carries on funding streak
Allogene tallies up $120m
The cancer therapy developer has secured $120m in a convertible note offering featuring the University of California office of the chief investment officer.
Pfizer coughs up funding for Biontech
Biontech, an immunotherapy spinout of Johannes Gutenberg University Mainz, has received an undisclosed amount of equity funding as part of a collaboration deal that could reach $425m.
Big deal: Ambys arrives at $140m investment
Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.
Ascentage tends to $150m series C
Ascentage, based on research at University of Michigan, has increased its total funding to more than $240m after closing a $150m series C round.

Other News

Investors take another slice of Lime
The Stanford-StartX Fund-backed electric scooter and bike rental service has raised $335m in a GV-led round that also included Uber.
Precision proves effective to close $110m series B
Duke Management Company and Osage University Partners have invested in the genome editing technology spinout from Duke University.
UCL helps inject $116m into Freeline
UCL and Syncona have both returned for Freeline's series B round, which will spur clinical development of the spinout's gene therapy for haemophilia B.
Humacyte engineers $150m deal
Fresenius Medical Care will purchase a 19% stake in Humacyte, which closed a $75m series C round in March 2018.
Precision BioSciences details $110m series B
Duke spinout Precision BioSciences, whose investors include Amgen and Baxter, has raised an initial $88m in series B funding out of a $110m target.

Editor's Picks

Big deal: Ambys arrives at $140m investment
Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.
Immunocore smashes European biotech records
Immunotherapy firm Immunocore, which started life at Oxford University, raises the largest biotech round in European history.
test reg

Login